Imelda Schuhmann

Feb 2, 2024 | ascpt.onlinelibrary.wiley.com | Christian Loesche |Damien Picard |Benjamin Van Hoorick |Imelda Schuhmann

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Leukotriene A4 Hydrolase (LTA4H) inhibitors have been investigated by the pharmaceutical industry for the treatment of neutrophil-driven inflammatory diseases. To date, no LTA4H inhibitors have reached the market, yet. WHAT QUESTION DID THIS STUDY ADDRESS? This study investigated the human pharmacokinetic (PK) to pharmacodynamic (PD) relationship and clinical safety of the potent and highly selective LTA4H inhibitor LYS006.